Finding its announcements…Reading the newest ones…Sorting them by kind…
CLVTClarivate Plc
Between its yearly and quarterly reports, a company must tell everyone about big news within four business days, by filing a short report called an 8-K. Results, a new boss, a big deal, new debt, a change of auditor, shareholder vote results: it all lands here first. Below is every 8-K Clarivate filed in the last two years, sorted by kind, with the opening of the company's own words for the newest ones.
Since Nov 10, 2024. Each bar is a month.
Another event the company chose to report publicly.
In the company's wordsOn November 4, 2026, Clarivate Plc issued a press release announcing the launch of cash tender offers by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
New results: figures on this page will update when the full quarterly or annual report is filed.
In the company's wordsOn November 3, 2026, Clarivate Plc (the “Company”) issued a press release announcing earnings for the third quarter ended September 30, 2026. The press release has been furnished with this Form 8-K as Exhibit 99.1 and is posted on the investor relations section of the Company’s website (ir.clarivate.com/). The information in this Item 2.02, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any filing pursuant to the …
Information shared with investors, often a presentation or press release.
In the company's wordsOn November 3, 2026, the Company posted to its website supplemental information related to revenue, earnings, and guidance. The supplemental information has been furnished with this Current Report on Form 8-K as Exhibit 99.2 and is posted on the investor relations section of the Company’s website (ir.clarivate.com/). The information in this Item 7.01, including Exhibit 99.2 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any filing pursuant to the Securities Act or the Exchange Act, except as …
Buying or selling a business changes what the company owns and how it earns money.
In the company's wordsOn October 6, 2026, Clarivate Plc (“Clarivate”) filed a Current Report on Form 8-K (the “Original 8-K”) to disclose that, among other things, the previously announced sale of its Life Sciences and Healthcare business was completed on October 6, 2026. In the Original 8-K, Clarivate indicated that the pro forma financial information required by Item 9.01(b) of Form 8-K would be filed no later than October 13, 2026, which is the fourth business day following completion of the Life Sciences and Healthcare business sale. This Current Report on Form 8-K/A (the “Current Report”) is being filed to provide such pro forma financial information.
Buying or selling a business changes what the company owns and how it earns money.
In the company's wordsOn October 6, 2026, Clarivate Plc (“Clarivate”) completed the previously announced sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC (“Buyer”) pursuant to the Stock and Asset Purchase Agreement (the “Purchase Agreement”), dated as of July 3, 2026, between certain subsidiaries of Clarivate and Buyer (the “Transaction”). At the closing of the Transaction (the “Closing”), Buyer paid to a wholly-owned subsidiary of Clarivate cash consideration of $500,000,000, subject to customary adjustments for cash, indebtedness, working capital and transaction expenses as more fully set forth in the Purchase Agreement, and an affiliate of Buyer issued to a …
New leaders or board members can bring a change in strategy.
In the company's wordsUpon the Closing and in connection with the Transaction, Henry Levy, Clarivate’s President, Life Sciences & Healthcare, terminated employment with a subsidiary of Clarivate. Pursuant to the terms of the retention agreement entered into between Mr. Levy and a subsidiary of Clarivate (the terms of which were previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on July 6, 2026), Clarivate entered into a separation agreement and release with Mr. Levy providing for the payments and benefits set forth in the retention agreement.
Another event the company chose to report publicly.
In the company's wordsOn October 6, 2026, Clarivate issued a press release announcing the completion of the Transaction. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Another event the company chose to report publicly.
In the company's wordsOn September 24, 2026, Clarivate Plc issued a press release announcing the expiration and results of the previously announced cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Another event the company chose to report publicly.
In the company's wordsOn September 23, 2026, Clarivate Plc issued a press release announcing the pricing terms of the previously announced cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Another event the company chose to report publicly.
In the company's wordsOn September 17, 2026, Clarivate Plc issued a press release announcing the launch of cash tender offer by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
New leaders or board members can bring a change in strategy.
In the company's wordsChange in Chief Financial Officer On July 24, 2026, Jonathan Collins, the Executive Vice President & Chief Financial Officer of Clarivate Plc (the “Company”) resigned from his position, effective August 7, 2026. Mr. Collins' departure is not as a result of any disagreement with the Company, its management, its Board of Directors, or the Company’s independent auditors. On July 29, 2026, the Company announced that Michael Easton, age 53, has been appointed as Executive Vice President & Chief Financial Officer, effective as of August 8, 2026. Mr. Easton has more than 25 years of experience in finance and accounting. Mr. Easton has been at the Company since June 2022, …
Information shared with investors, often a presentation or press release.
In the company's wordsOn July 29, 2026, the Company announced that Michael Easton had been appointed as Executive Vice President & Chief Financial Officer, effective as of August 8, 2026. The Company’s press release dated July 29, 2026 announcing the appointment of Michael Easton is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document …
New results: figures on this page will update when the full quarterly or annual report is filed.
In the company's wordsOn July 29, 2026, Clarivate Plc (the “Company”) issued a press release announcing earnings for the second quarter ended June 30, 2026. The press release has been furnished with this Form 8-K as Exhibit 99.1 and is posted on the investor relations section of the Company’s website (ir.clarivate.com/). The information in this Item 2.02, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any filing pursuant to the Securities Act …
Information shared with investors, often a presentation or press release.
In the company's wordsOn July 29, 2026, the Company posted to its website supplemental information related to revenue, earnings, and guidance. The supplemental information has been furnished with this Current Report on Form 8-K as Exhibit 99.2 and is posted on the investor relations section of the Company’s website (ir.clarivate.com/). The information in this Item 7.01, including Exhibit 99.2 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any filing pursuant to the Securities Act or the Exchange Act, except as …
A major new contract can change what the company sells, spends or owes.
In the company's wordsOn July 3, 2026, certain subsidiaries of Clarivate Plc (“Clarivate” or the “Company”) entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with an affiliate of Altaris, LLC (“Buyer”), pursuant to which, among other things, Clarivate has agreed to sell its Life Sciences and Healthcare business to Buyer (the “Transaction”). The consummation of the Transaction is subject to certain specified closing conditions, including the receipt of certain regulatory approvals and other customary closing conditions, including, subject to certain materiality exceptions, the accuracy of each party’s representations and warranties and each party’s compliance with its …
New leaders or board members can bring a change in strategy.
In the company's wordsOn July 3, 2026, a subsidiary of Clarivate entered into a retention agreement with Henry Levy, Clarivate’s President, Life Sciences & Healthcare, to encourage his continued commitment toward the completion of the Transaction. Under the terms of the retention agreement, (i) if the closing of the Transaction occurs prior to March 31, 2027, any unvested Clarivate restricted stock unit awards outstanding as of immediately prior to the closing of the Transaction will vest in full, subject to Mr. Levy’s continued employment through such time, (ii) upon the closing of the Transaction, any unvested Clarivate performance share units will be cancelled for no consideration and (iii) …
Information shared with investors, often a presentation or press release.
In the company's wordsOn July 6, 2026, Clarivate Plc (“Clarivate” or the “Company”) announced an agreement to sell its Life Sciences and Healthcare business to an affiliate of Altaris, LLC. The purchase agreement for the transaction includes customary representations, warranties and covenants by the parties. The press release has been furnished with this Current Report on Form 8-K as Exhibit 99.1 and is posted on the investor relations section of the Company’s website (http://ir.clarivate.com/). The Company will be delivering the investor presentation on the conference call referred to in the press release, and will post to its website supplemental information related to the transaction. The …
New leaders or board members can bring a change in strategy.
In the company's wordsMourad, President, Intellectual Property of Clarivate Plc (the “Company”) will depart from his position, effective June 9, 2026. Following such date, Mr. Mourad will remain employed by the Company in a non-executive advisory role until September 30, 2026. In connection with the transition of his role, on June 6, 2026, the Company entered into a separation agreement with Mr. Mourad. Pursuant to the terms of the separation agreement, in exchange for his execution and non-revocation of a release of claims and continued compliance with the terms of his agreement (including his restrictive covenants), Mr. Mourad will receive (i) a cash payments equal to $450,000 representing a …
Information shared with investors, often a presentation or press release.
In the company's wordsOn June 8, 2026, the Company announced that Simon Webster will assume the role of President, Intellectual Property, effective as of June 10, 2026. The Company’s press release dated June 8, 2026 announcing the appointment of Simon Webster is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the …
How shareholders voted on board members and proposals.
Another event the company chose to report publicly.
New results: figures on this page will update when the full quarterly or annual report is filed.
Information shared with investors, often a presentation or press release.
New leaders or board members can bring a change in strategy.
New results: figures on this page will update when the full quarterly or annual report is filed.
Information shared with investors, often a presentation or press release.
Information shared with investors, often a presentation or press release.
Losing a major agreement can affect future sales or costs.
Another event the company chose to report publicly.
New results: figures on this page will update when the full quarterly or annual report is filed.
Information shared with investors, often a presentation or press release.
A major new contract can change what the company sells, spends or owes.
New borrowing adds to what the company owes and the interest it pays.
New leaders or board members can bring a change in strategy.
Information shared with investors, often a presentation or press release.
New results: figures on this page will update when the full quarterly or annual report is filed.
Information shared with investors, often a presentation or press release.
New leaders or board members can bring a change in strategy.
A major new contract can change what the company sells, spends or owes.
New borrowing adds to what the company owes and the interest it pays.
Information shared with investors, often a presentation or press release.
Another event the company chose to report publicly.
How shareholders voted on board members and proposals.
Another event the company chose to report publicly.
New results: figures on this page will update when the full quarterly or annual report is filed.
Information shared with investors, often a presentation or press release.
New leaders or board members can bring a change in strategy.
New results: figures on this page will update when the full quarterly or annual report is filed.
Information shared with investors, often a presentation or press release.
Information shared with investors, often a presentation or press release.
New leaders or board members can bring a change in strategy.